Impact Partnership Wealth LLC Makes New $467,000 Investment in Royalty Pharma plc (NASDAQ:RPRX)

Impact Partnership Wealth LLC acquired a new stake in Royalty Pharma plc (NASDAQ:RPRX) during the 4th quarter, HoldingsChannel.com reports. The fund acquired 18,323 shares of the biopharmaceutical company’s stock, valued at approximately $467,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. raised its position in Royalty Pharma by 58.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 3,001,603 shares of the biopharmaceutical company’s stock valued at $84,915,000 after purchasing an additional 1,103,341 shares in the last quarter. Two Sigma Advisers LP increased its stake in Royalty Pharma by 44.7% in the third quarter. Two Sigma Advisers LP now owns 3,033,200 shares of the biopharmaceutical company’s stock valued at $85,809,000 after purchasing an additional 936,900 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in Royalty Pharma during the third quarter worth approximately $14,898,000. Geode Capital Management LLC lifted its position in shares of Royalty Pharma by 6.1% during the 3rd quarter. Geode Capital Management LLC now owns 7,265,786 shares of the biopharmaceutical company’s stock worth $205,562,000 after buying an additional 417,490 shares during the last quarter. Finally, Dark Forest Capital Management LP grew its position in shares of Royalty Pharma by 2,974.4% in the 2nd quarter. Dark Forest Capital Management LP now owns 338,675 shares of the biopharmaceutical company’s stock valued at $8,931,000 after buying an additional 327,659 shares during the last quarter. 54.35% of the stock is currently owned by hedge funds and other institutional investors.

Royalty Pharma Stock Up 1.8 %

RPRX opened at $30.62 on Friday. Royalty Pharma plc has a 52 week low of $24.05 and a 52 week high of $31.66. The business has a 50 day moving average price of $26.67 and a two-hundred day moving average price of $27.31. The company has a quick ratio of 1.54, a current ratio of 1.54 and a debt-to-equity ratio of 0.64. The company has a market cap of $18.04 billion, a PE ratio of 15.87 and a beta of 0.47.

Royalty Pharma Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 21st will be issued a dividend of $0.22 per share. The ex-dividend date of this dividend is Friday, February 21st. This is an increase from Royalty Pharma’s previous quarterly dividend of $0.21. This represents a $0.88 annualized dividend and a dividend yield of 2.87%. Royalty Pharma’s dividend payout ratio (DPR) is currently 43.52%.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. StockNews.com upgraded shares of Royalty Pharma from a “hold” rating to a “buy” rating in a research note on Tuesday, November 5th. TD Cowen raised Royalty Pharma to a “strong-buy” rating in a research report on Tuesday, December 24th. Finally, Citigroup dropped their price target on Royalty Pharma from $60.00 to $40.00 and set a “buy” rating on the stock in a research note on Friday, October 25th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $41.67.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.